Table 2.

Follow-up study patient characteristics

	D0 (n = 14)	M1 (n = 14)	M6 (n = 14)	M12 (n = 14)
Sex, male, n (%)	13 (93%)	–	–	–
Age (years)	45.1 ± 5.2	–	–	–
BMI (kg/m2)	26.0 ± 2.8	24.7 ± 2.9	24.7 ± 2.1	24.8 ± 2.5
HbA1c (%) (mmol/mol)	8.8 ± 1.7 (73 ± 18.6)	6.5 ± 1.8* (48 ± 19.7)	5.3 ± 0.3* (34 ± 3.3)	5.4 ± 0.2* (36 ± 2.2)
Glucose (mmol/l)	14.7 ± 7.1	6.3 ± 1.0*	5.3 ± 1.4*	5.8 ± 1.5*
eGFR (ml min−1 1.73 m−2)	18 ± 9	54 ± 19*	54 ± 15*	54 ± 11*
Median proteinuria (g/24 h) (IQR)	0.73 (0.36–1.30)	0.66 (0.28–1.15)	0.41 (0.17–0.98)	0.37 (0.14–1.10)
Systolic blood pressure (mmHg)	153 ± 15	129 ± 21*	133 ± 20*	131 ± 14*
Diastolic blood pressure (mmHg)	87 ± 11	78 ± 11	78 ± 11	78 ± 6
Haemoglobin (mmol/l)	7.6 ± 0.5	6.6 ± 0.9*	7.4 ± 0.9	8.0 ± 1.0
Haematocrit (l/l)	0.37 ± 0.03	0.33 ± 0.05	0.37 ± 0.04	0.40 ± 0.05
Diabetes after SPK, n (%)	–	1 (7%)	2 (14%)	0 (0%)
Smoking, n (%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Acetylsalicylic acid, n (%)	3 (21%)	1 (7%)	1 (7%)	4 (29%)
Antihypertensive drugs, n (%)
ACE inhibitor	9 (64%)	2 (14%)*	3 (21%)*	3 (21%)*
Angiotensin-II antagonist	9 (64%)	1 (0%)	1 (0%)	1 (0%)
Calcium antagonist	8 (57%)	4 (29%)	5 (36%)	8 (57%)
Diuretic	10 (71%)	1 (0%)	1 (7%)*	2 (14%)*
β-Blocker	8 (57%)	6 (43%)	4 (29%)	4 (29%)
Statin, n (%)	8 (57%)	2 (14%)*	2 (14%)*	3 (21%)*
Steroid-free, alemtuzumab induction, n (%)	–	14 (100%)	–	–
Immunosuppressive drugs, n (%)	–
Cyclosporine		1 (7%)	2 (14%)	1 (7%)
Tacrolimus		12 (86%)	11 (79%)	11 (79%)
Prednisone		1 (7%)	4 (29%)†	4 (29%)†
Everolimus		1 (7%)	1 (7%)	2 (14%)
Mycophenolate mofetil		14 (100%)	13 (93%)	14 (100%)

Parametric data are presented as mean ± SD. Nonparametric data are presented as median and IQR. Categorical data are presented as frequency and percentage

*p < 0.05 vs D0; ^† p < 0.05 vs M1

ACE, angiotensin-converting enzyme; D0, before transplantation; M1, M6 and M12, 1, 6 and 12 months post-transplantation, respectively